Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber
"A major endorsement for the medical cannabis sector"

Pfizer to acquire Arena Pharmaceuticals

Pfizer and Arena Pharmaceuticals announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion. The boards of directors of both companies have unanimously approved the transaction.

“The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options,” said Mike Gladstone, Global President & General Manager, Pfizer Inflammation and Immunology. “Utilizing Pfizer’s leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases.”

According to CBDX, a medical cannabis and wellness brand, this announcement is just the latest case of big pharma becoming unafraid of touching cannabinoid-based research. Nawan Butt, Portfolio Manager: “This acquisition displays the interest big pharma is taking in the fast-evolving world of cannabinoids. We are encouraged by the acquisition as it provides more resources and a wider platform for pharmaceutical development of cannabinoids. Overall, this transaction is in line with Pfizer's long-term focus on research and a great win for our investors.”

For more information:
Pfizer
www.pfizer.com 

 

 

CBDX
www.cbdx.com 

Publication date: